Nabil S Andrawis
Overview
Explore the profile of Nabil S Andrawis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
18
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Flack J, Schlaich M, Weber M, Sassi-Sayadi M, Narkiewicz K, Clozel M, et al.
Hypertension
. 2025 Jan;
PMID: 39840441
Background: Black individuals frequently present with resistant hypertension and disproportionately increased cardiovascular risk. We investigated the blood pressure (BP)-lowering effect of the dual endothelin receptor antagonist aprocitentan in Black individuals...
2.
Bhatt D, Bays H, Miller M, Cain 3rd J, Wasilewska K, Andrawis N, et al.
Nat Med
. 2024 Mar;
30(6):1788-1789.
PMID: 38438737
No abstract available.
3.
Bhatt D, Bays H, Miller M, Cain 3rd J, Wasilewska K, Andrawis N, et al.
Nat Med
. 2023 Jun;
29(7):1782-1792.
PMID: 37355760
Pegozafermin, a long-acting glycopegylated analog of human fibroblast growth factor 21, is in development for the treatment of severe hypertriglyceridemia (SHTG) and nonalcoholic steatohepatitis. Here we report the results of...
4.
Ammann E, OBrien E, Milentijevic D, Kharat A, Talbot D, Canovatchel W, et al.
Heliyon
. 2023 Feb;
9(2):e13258.
PMID: 36846680
Background: Per treatment guidelines, resistant hypertension is defined as uncontrolled blood pressure (BP) while taking 3 concomitant antihypertensives (AHTs) or controlled BP while taking ≥4 AHTs. Characteristics, AHT therapy use,...